Gamida Cell presents new data on allogeneic stem cell therapy Omidubicel, GDA-20

Gamida Cell shared new data on the impact of the company’s proprietary nicotinamide technology on its allogeneic stem cell therapy omidubicel and investigational natural killer cell therapy candidate GDA-201 at the Society for Immunotherapy of Cancer’s Annual Meeting in San Diego, CA. Both omidubicel and GDA-201 are powered by Gamida Cell’s proprietary NAM technology, which enhances and expands cells to create potentially curative cell therapies for patients with cancer. Omidubicel was approved under the brand name Omisirge by the U.S. FDA in April 2023 for allogeneic stem cell transplant; GDA-201 is in Phase 1 study for the treatment of non-Hodgkin lymphoma. Data on the first three cohorts of the Phase 1 study of GDA-201 were recently reported. “The data presented at SITC further our understanding of the effect of NAM in enhancing and expanding cells,” said Ronit Simantov, Chief Medical and Scientific Officer of Gamida Cell. “Our data characterize the unique cellular composition of omidubicel, which is enriched in myeloid populations and dendritic cells, providing a potential mechanism for rapid engraftment and immune reconstitution, and is associated with lower infection rates observed in patients transplanted with omidubicel. Similarly, our data on GDA-201 demonstrate the unique, active phenotype of our NK cells expanded in the presence of NAM.”